EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacogenomic testing for major depressive disorder in British Columbia, Canada: Recommendations from a public deliberation

Louisa Edwards, Colene Bentley, Kieran C O'Doherty, Mary Bunka, Carly Pistawka, Linda Riches, Lisa Ridgway, Chad Bousman, Jehannine Austin, Stirling Bryan

Journal of Affective Disorders · 2026-09 · 409 · 121910

DOI: 10.1016/j.jad.2026.121910 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Affective Disorders, 2026-09. Verfasst von Louisa Edwards und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Population & Public Health, University of British Columbia (UBC), Vancouver, Canada. Electronic address: louisa.edwards@ubc.ca. Hauptthemen laut MEDLINE: Major Depressive Disorder, Pharmacogenomic Testing, Pharmacogenetics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health, British Columbia, Genome British Columbia, Canadian Mental Health Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Pharmacogenomic (PGx) testing for major depressive disorder (MDD) can reduce healthcare spending and improve patient outcomes. However, concerns about health equity, data privacy, and secondary usage of data require deliberation. We sought recommendations from members of the general public for policymakers' consideration. METHODS: A four-day public deliberation was held in Vancouver, British Columbia (BC), from November-December 2024. Invitations were mailed to 15,000 randomly-selected households in BC. Participant selection maximized socio-demographic diversity. Participants received an information booklet and heard from expert speakers before discussing whether and how PGx testing for MDD should be implemented. Participants then generated and voted on recommendation statements. Finally, participants engaged with policy-/decision-maker panelists. Sessions were audio recorded and transcribed. RESULTS: Thirty participants generated 15 recommendations. Publicly funding PGx testing for MDD was supported under certain conditions. Participants unanimously called for strict test reporting standards, in line with evidence-based prescribing guidelines. Healthcare professional (HCP) education was seen as necessary, with ongoing access to PGx experts. To enhance accessibility and acceptability, the group suggested re-naming this "PGx testing (medication compatibility testing)" and conducting a targeted awareness/education campaign. However, participants wanted additional efficacy data collected across diverse ancestry groups to ensure PGx testing benefited everyone. While they agreed test results could be shared between HCPs, they wanted further public engagement on using PGx results in research without consent. CONCLUSIONS: Knowledge gained throughout the event appeared to reduce concerns around data privacy, highlighting the importance of pre-implementation education and awareness. These recommendations provide guidance to policymakers considering PGx implementation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Major Depressive DisorderPharmacogenomic TestingPharmacogeneticsHumansBritish ColumbiaFemaleMaleAdult

Stichwörter der Autor:innen

Major depressive disorderMental healthPharmacogenetic testingPharmacogenomic testingPublic deliberationPublic policy

Autor:innen und Institutionen

  • School of Population & Public Health, University of British Columbia (UBC), Vancouver, Canada. Electronic address: louisa.edwards@ubc.ca.
  • Consultant.
  • University of Guelph, Guelph, Canada.
  • School of Population & Public Health, University of British Columbia (UBC), Vancouver, Canada.
  • Patient Research Partner, Vancouver, Canada.
  • Department of Medical Genetics, University of Calgary, Calgary, Canada.

Förderung

  • Ministry of Health, British Columbia
  • Genome British Columbia
  • Canadian Mental Health Association

Zitieren

APA

Edwards, L., Bentley, C., O'Doherty, K. C., Bunka, M., Pistawka, C., Riches, L., Ridgway, L., Bousman, C., Austin, J., & Bryan, S. (2026). Pharmacogenomic testing for major depressive disorder in British Columbia, Canada: Recommendations from a public deliberation. Journal of Affective Disorders, 409, 121910. https://doi.org/10.1016/j.jad.2026.121910

Vancouver

Edwards L, Bentley C, O'Doherty KC, Bunka M, Pistawka C, Riches L, et al. Pharmacogenomic testing for major depressive disorder in British Columbia, Canada: Recommendations from a public deliberation. Journal of Affective Disorders. 2026;409:121910. doi:10.1016/j.jad.2026.121910

BibTeX
@article{Edwards2026,
  author = {Edwards, Louisa and Bentley, Colene and O'Doherty, Kieran C and Bunka, Mary and Pistawka, Carly and Riches, Linda and Ridgway, Lisa and Bousman, Chad and Austin, Jehannine and Bryan, Stirling},
  title = {Pharmacogenomic testing for major depressive disorder in British Columbia, Canada: Recommendations from a public deliberation},
  journal = {Journal of Affective Disorders},
  year = {2026},
  volume = {409},
  pages = {121910},
  doi = {10.1016/j.jad.2026.121910}
}
Kostenlos starten →